Weekly patch available for patients with Alzheimer’s

Corium Inc. announced that Adlarity transdermal treatment is available to prescribe in the U.S. for patients with Alzheimer’s.

"We are thrilled to be launching Adlarity [donepezil transdermal system] and feel fortunate for the opportunity to provide patients living with Alzheimer's dementia, their families and their caregivers a new, innovative way to deliver donepezil in a consistent and well-tolerated option,” Corium President and CEO Perry Sternberg, said in a company press release.

Adlarity is a weekly transdermal patch that delivers donepezil through the skin in doses of 5 mg or 10 mg, according to the release. Prescribers can switch patients who were taking 5 mg or 10 mg of oral donepezil directly over to the once-weekly patch. It continuously delivers consistent doses of donezepil, enabling a favorable overall gastrointestinal side effect profile, the company said.

The FDA approved the Adlarity patch in March 2022. Corium said it is working with CMS to expand access to this new treatment option, with coverage expected in 2023.

The company is phasing in availability of the treatment, with plans for a nationwide launch in 2023.